Denali Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell DNLI and other ETFs, options, and stocks.

About DNLI

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. 

CEO
Ryan J. Watts
CEORyan J. Watts
Employees
503
Employees503
Headquarters
San Francisco, California
HeadquartersSan Francisco, California
Founded
2013
Founded2013
Employees
503
Employees503

DNLI Key Statistics

Market cap
3.44B
Market cap3.44B
Price-Earnings ratio
-7.52
Price-Earnings ratio-7.52
Dividend yield
Dividend yield
Average volume
1.89M
Average volume1.89M
High today
$22.15
High today$22.15
Low today
$20.92
Low today$20.92
Open price
$21.02
Open price$21.02
Volume
2.19M
Volume2.19M
52 Week high
$23.77
52 Week high$23.77
52 Week low
$12.58
52 Week low$12.58

Stock Snapshot

With a market cap of 3.44B, Denali Therapeutics(DNLI) trades at $21.62. The stock has a price-to-earnings ratio of -7.52.

On 2026-06-15, Denali Therapeutics(DNLI) stock moved within a range of $20.92 to $22.15. With shares now at $21.62, the stock is trading +3.3% above its intraday low and -2.4% below the session's peak.

Trading volume for Denali Therapeutics(DNLI) stock has reached 2.19M, versus its average volume of 1.89M.

Over the past 52 weeks, Denali Therapeutics(DNLI) stock has traded between a high of $23.77 and a low of $12.58.

Over the past 52 weeks, Denali Therapeutics(DNLI) stock has traded between a high of $23.77 and a low of $12.58.

DNLI News

Simply Wall St 3d
Should Denali’s Pivot to BEACON Precision Trial After BIIB122 Setback Require Action From Denali Investors?

Denali Therapeutics and Biogen previously halted joint development of BIIB122 for idiopathic Parkinson’s disease after the Phase 2b LUMA trial did not meet its...

Should Denali’s Pivot to BEACON Precision Trial After BIIB122 Setback Require Action From Denali Investors?

Analyst ratings

94%

of 18 ratings
Buy
94.4%
Hold
5.6%
Sell
0%

People also own

Based on the portfolios of people who own DNLI. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.